Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

tinues," "commitment," "providing support," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Novartis Ph+ CML products or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with a Novartis Ph+ CML product to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any Novartis Ph+ CML product will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that any Novartis Ph+ CML product will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the infor
'/>"/>
SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... (PRWEB) April 28, 2015 The ... a Massachusetts-based multi-stakeholder, non-profit organization dedicated to transforming ... a shared global system for clinical research, announced ... an innovative new type of clinical research event ... of clinical research is changing,” said Greg Koski, ...
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
Breaking Biology Technology:ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... Calif., Oct. 28 Voler Systems ( http://www.volersystems.com ), ... 50% growth over the same period last year. , ... our strong results. Medical firms are turning to Voler ... to production of devices for human use. We remain ...
... 27 Microfluidics International Corporation (OTC Bulletin Board: MFLU) ... 2009 financial results on Monday, November 2, 2009, after ... http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO ) , Michael C. ... Byczko, Vice President of Finance and Chief Accounting Officer, ...
... response to requests from clients, Schulman Associates IRB (Schulman) has ... Canadian Board,s first official meeting is scheduled for this week. ... the U.S. and Canada, Canadian and U.S. Board members will ... "Our clients have asked us to provide review services in ...
Cached Biology Technology:Voler Systems Reports 50% Growth 2Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 2Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009 3Schulman Associates IRB Establishes an Institutional Review Board in Canada 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... students at Ontario universities a unique opportunity to ... associated technologies, or explore the societal outcomes, impacts ... their fellowship experience, students acquire a deeper understanding ... have across the spectrum of human and animal ...
... BATON ROUGE The International Institute for Species Exploration ... from around the world announced their picks for the ... top picks is Halieutichthys intermedius , a pancake ... at LSU,s Museum of Natural Science, and colleagues. ...
... The partners in the project, which is entitled ... and the agricultural faculty of the University of Pannonia. ... Fund and its objective is to establish a knowledge ... border region, to improve their efficiency and to ensure ...
Cached Biology News:OGI awards summer research fellowships to 7 Ontario students 2OGI awards summer research fellowships to 7 Ontario students 3Fish species discovered by LSU researcher makes 2011 top 10 list 2
FRACTALKINE [Human] (Recombinant)...
... For the ultimate in utility and flexibility ... meet the needs of the researcher. They ... dimensions or as sheet material that can ... These isolators are autoclavable and non-cytotoxic and ...
Argon Calibration Source...
SHEEP ANTI ESCHERICHIA COLI...
Biology Products: